Clinical Trials
22 trialsNCT06814496 2026-05-20
RABBIT
University of Arizona
Phase 1/2 Recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT04752722 2026-04-30
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
Phase 1/2 Recruiting
NCT07232602 2026-04-24
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07222488 2026-04-23
MK-3120-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07421700 2026-04-20
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT06470282 2026-02-18
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
Phase 1/2 Recruiting
NCT07030257 2026-02-18
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
Phase 1/2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT04724018 2025-11-04
Sacituzumab Govitecan Plus EV in Metastatic UC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06394570 2025-09-15
STAR-EV
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT03185468 2025-09-08
Intervention of Bladder Cancer by CAR-T
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06364956 2025-08-11
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT06732531 2025-01-09
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2 Recruiting
NCT04106115 2024-12-04
DURANCE
University College, London
Phase 1/2 Recruiting
NCT06341400 2024-12-04
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Zhujiang Hospital
Phase 1/2 Recruiting
NCT03844256 2022-08-12
CRIMI
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Recruiting